Patisiran for ATTR Cardiomyopathy Gets FDA Panel Thumbs Up

An FDA advisory committee voted 9 to 3 that the benefits of patisiran outweigh the risks for ATTR cardiomyopathy, but many questioned whether the benefit is clinically meaningful.

Related Keywords

Georgia ,United States ,Texas ,Maryland ,Baltimore ,Atlanta ,Dallas ,Canada ,Emory University ,C Noel Bairey Merz ,Ravi Thadhani ,Javed Butler ,Los Angeles ,Edward Kasper ,Johns Hopkins School Of Medicine ,Drug Administration ,Smidt Heart Institute ,Renal Drugs Advisory Committee ,Sinai Medical Center ,Baylor Scott White Research Institute ,Medscape Cardiology ,Bairey Merz ,Cedars Sinai Medical Center ,Baylor Scott ,White Research Institute ,Johns Hopkins School ,Amyloidosis ,Transthyretin Related Amyloidosis ,Cardiomyopathy , ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Heart ,Interference ,Rare Diseases ,